Global Rules Could Cut Costs and Speed Access to GLP-1 Drugs
UCSF research shows that international rules for biosimilars, mimics of biologic drugs like Ozempic and insulin, need to improve and match each another to encourage biosimilar development, testing, and approval. This would dramatically improve drug affordability just like generics has done.